Research Progress of Chimeric Antigen Receptor Therapy in Tumor Immunetherapy
YANG Diya1, KONG Xianghui2, ZHOU Xiumei2*
CAR (chimeric antigen receptor) is a fusion protein constructed by genetic engineering technology that can be used to reprogram immune cells to specifically target and kill tumor cells expressing specific antigens. So far, most researches focus on CAR-T cell therapy. CAR-T cell therapy has made breakthroughs in haematological cancers, and seven drugs have been approved for clinical treatment. While researchers continue to study CAR-T cell therapy in depth, they also begin to look for new immune effector cells, CAR-NK (CAR natural killer cell), CAR-NKT (CAR NK T cell) and CAR-MP (CAR-macrophage) therapies are being the new strategies for tumor immunotherapy. Despite CAR-based strategies expansion, the field also faces challenges such as effective targeting of solid tumors, reducing toxic side effects during treatment. This review focuses on the research progresses in current CAR-modified cell therapies.
CN
EN